ArticleScientific reports2026
Feasibility of
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Aortic aneurysm (AA) is a disease where aortic wall loses its elasticity, showing fibrosis. Fibroblast activation protein (FAP) expression can be evaluated using radiolabeled FAP-inhibitor (FAPI) PET in fibrosis. We investigated FAP expression in AA and the feasibility of 68Ga-FAPI PET for AA imaging. Twenty AA patients who were planned for resection were prospectively enrolled. Nine lung cancer patients were used as control. Markers including FAP expression were assessed in AA and the remote aorta. Preoperative 68Ga-FAPI-46 PET was evaluated visually and quantitatively using maximal standard uptake value (SUVmax), and were compared with the growth rate of AA. FAP expression was increased in Western blotting (P = 0.014), both in intima and adventitia of AA. The SUVmax was significantly correlated with the FAP expression (r = 0.678, P = 0.008). The SUVmax of AA was significantly higher than the aortic SUVmax of the control (P = 0.018). The growth rate of AA was different between the uptake grade groups (P = 0.029), and correlated with SUVmax (r = 0.625, P = 0.013). FAP expression is variably increased in AA and possibly related to the progression of AA. 68Ga-FAPI PET can be a promising imaging for evaluating FAP expression of AA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.